LCL-dBNRF1 exhibited slower growth than LCLs-WT. by Ken Sagou (1945318)

DAF-16/FOXO is Required for Locomotory Healthspan and Lifespan Benefits of Genetic Glycolysis Disruption. by Brian Onken (86790)

“…<i>daf-16</i> mutants are documented to have lowered locomotory ability vs. WT later in life [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref091" target="_blank">91</a>, <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref092" target="_blank">92</a>]; we note that, although comparison of scores across experiments is not possible due to variation in baseline values, the swimming rate of <i>daf-16(mgDf50)</i> control animals was slightly lower than WT controls on the same day of life (in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.g001" target="_blank">Fig 1C</a>; mean of 46.17 head thrashes/30 sec. for <i>daf-16</i> vs. 52.17 head thrashes/30 sec. for WT on day 10). …”

Excel spreadsheet containing, in separate sheets, the underlying numerical data and statistical analysis for Figure panels 1A-1D, 2D-2H, 3B, 4B, 4C, 4E, 5D, 5F, 5G, 5I-5M, 6A-6D, 6... by Yuru Wang (846969)

Longitudinal YU2 gp120 WT-reactive CD4i IgG binding antibodies elicited in RV144 and RV305 (related to Fig 1). by LaTonya D. Williams (3140490)

Comparison of mean daily IAA intake quantity before and after digestibility adjustments. by Bi Xue Patricia Soh (21100364)

Subjects:

Expression of genes encoding proteins involved in protein folding, quality control, trafficking and ER-associated degradation differentially expressed in liver of <i>Fmo5</i><sup><... by Ian R. Phillips (5074121)

Simulated regional mean wetland seasons. by Nic Gedney (19762301)

RNF5 loss decreases ERK and Akt activation, CDK1 and Smo expression and KSHV lytic replication in PEL cells. by Xiaojuan Li (351842)

Cytotoxicity (as of %Control) IC₅₀ value (mean ±SD in µM) of the tested compounds vs. positive controls Cisplatin and doxorubicin against other malignancy’ cell lines ad... by MohammedBashar Al-Qazzan (22439236)

Demographic data of the ED visits due hand injuries and subsequent hand operations, 2020 compared with mean of reference years 2017–2019. by Ilari Kuitunen (11084096)

Effect of dexmedetomidine (5 μg∙kg⁻¹ or 50 μg∙kg⁻¹) at experimental recording (Protocol 1). by Yoichiro Kitajima (4319455)

Subjects:

Sample means, SDs, and selected correlations. by Erik Lykke Mortensen (7239170)

Results of two-way repeated measure ANOVAs for various HRV indicators. by Duyan Geng (12072181)

Subjects:

Tension ratings at different period under taVNS or staVNS. by Duyan Geng (12072181)

Subjects:

Descriptive statistics of HRV indicators among the three recordings (baseline, stimulation, recovery) under taVNS or staVNS conditions. by Duyan Geng (12072181)

Subjects:

Ear stimulation targets used of taVNS or staVNS. by Duyan Geng (12072181)

Subjects:

Descriptive statistics of Stimulation intensity, pain ratings and tension ratings under different stimulation conditions. by Duyan Geng (12072181)

Subjects:

Differences in stimulation intensity between various parameters. by Duyan Geng (12072181)

Subjects:

Procedure for study 1. by Duyan Geng (12072181)

Subjects:

Stimulation response by parameter over time. by Duyan Geng (12072181)

Subjects: